Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). It also engages in developing CELsignia diagnostic platform. The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota.

Celcuity Inc.

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Hold rating on Celcuity today and set a price target of $94.00. Ramakanth covers the He...

H.C. Wainwright Sticks to Their Hold Rating for Celcuity (CELC)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Celcuity (CELC – Research Report) and BioNTech SE (B...

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alpha Teknova (TKNO – Research Report), LENZ Therape...

Current Quarter	$-1.07	Next Quarter	$-1.17
Current Year	$-3.97	Next Year	$-0.69
QoQ Growth	-9.3%	YoY Growth	+82.6%
3Y EPS CAGR	N/A	Target Price	$128.60
Consensus	Buy	Upside	+10.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CELC	$116.91	+1.16%	334.68K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CELC	$116.91	+1.2%	334.68K
3
4
5
6

CELC

CELC

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get Celcuity Inc. Data in Excel

Get Celcuity Inc. Data in Excel